Capital Research Global Investors Immuno Gen, Inc. Transaction History

Capital Research Global Investors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $28 Million - $68.8 Million	-7,095,570 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $20.1 Million - $26.3 Million	-2,335,430 Reduced 24.76%	7,095,570 $67.2 Million
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $37.3 Million - $47.7 Million	3,923,000 Added 71.22%	9,431,000 $91.8 Million
Q1 2018 May 15, 2018	BUY	$6.7 - $12.95 $36.9 Million - $71.3 Million	5,508,000 New	5,508,000 $57.9 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

Stay updated on Capital Research Global Investors with notifications on news.